Distributing Information to Members or Practitioners During March 1, 2020 – June 30, 2022

NCQA will not require certain mail notification to members or practitioners through the March 1, 2020 – June 30, 2022 time frame. Annual mailings planned during this period may be suspended until the organization’s next scheduled cycle.

This exception applies to the elements in the table below. It identifies applicable elements in HP 2019, 2020, and 2021; however, guidance applies to applicable requirements in derivative products (e.g., MBHO, UM-CR-PN).

Applicable elements in HP 2019, 2020, and 2021

HP 2020 & 2021HP 2019
NET 4, Element A: Notification of TerminationNET 5, Element A
NET 4, Element B: Continued Access to PractitionersNET 5, Element B
NET 5, Element J: Availability of DirectoriesNET 6, Element L
Policies and Procedures, Section 2UM 4, Element G
UM 2, Element B: Availability of CriteriaUM 2, Element B
UM 11, Element A: Pharmaceutical Management ProceduresUM 11, Element A
UM 11, Element B: Pharmaceutical Restrictions/PreferencesUM 11, Element B
ME 1, Element B: Distribution of Rights StatementRR 1, Element B
ME 2, Element A: Subscriber InformationRR 3, Element A


Although NCQA will not require organizations to submit files for review during March 1, 2020 – June 30, 2022, we have not waived the requirement for time-sensitive notices to members regarding specific clinical circumstances or for UM or pharmaceutical recalls (UM 4 – 11).

  • Save

    Save your favorite pages and receive notifications whenever they’re updated.

    You will be prompted to log in to your NCQA account.

  • Email

    Share this page with a friend or colleague by Email.

    We do not share your information with third parties.

  • Print

    Print this page.